Dr. James S. Lewis II, Antibiotic Susceptibility Test Expert, Joins as Chair of Selux Diagnostics’ Clinical Advisory BoardOctober 18, 2022
Science is a Puzzle: Selux Diagnostics Director of Research and Development Kelly Flentie On Collaboration, Idea Diversity, and Solving One of the Biggest Medical Problems of Our TimeApril 26, 2022
Selux secures $50M for commercialization of antimicrobial susceptibility testing platformMarch 3, 2022
Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP PlatformOctober 19, 2021
Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) PlatformSeptember 28, 2021
Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid SamplesSeptember 28, 2021
Health Tech: Aleksandar Vacic On How Selux Diagnostics’s Technology Can Make An Important Impact In Our Overall WellnessAugust 19, 2021